Alto Neuroscience (ANRO) Free Cash Flow (2023 - 2026)

Alto Neuroscience has disclosed Free Cash Flow across 4 years of filings, most recently posting -$28.0 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$28.0 million, down 69.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$63.2 million (down 15.26% YoY), and the FY2025 annual result was -$51.8 million, down 4.63% from the prior year.
• Free Cash Flow came in at -$28.0 million for Q1 2026 at Alto Neuroscience, down from -$11.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$6.7 million in Q2 2023 to a low of -$28.0 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$12.0 million (2023), against an average of -$12.6 million.
• Across the five-year window, Free Cash Flow slumped 79.91% in 2024 and grew 22.1% in 2025, its largest moves.
• Alto Neuroscience's Free Cash Flow stood at -$12.0 million in 2023, then declined by 12.78% to -$13.5 million in 2024, then climbed by 14.87% to -$11.5 million in 2025, then sank by 143.42% to -$28.0 million in 2026.
• The last three Free Cash Flow figures came in at -$28.0 million (Q1 2026), -$11.5 million (Q4 2025), and -$9.9 million (Q3 2025), per Business Quant data.